Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 19-Mar-24 2:30 PM View:  | Schobel Alexander Mark Chief Innovation/Tech Officer | Aquestive Therapeutics, Inc. (AQST) | 15-Mar-24 | Private Sale (Planned) | 50,000 | $6.00 | $300,000.00 | (5%) 1.03M to 984.48K | |
| 12-Mar-24 1:46 PM View: | Wargacki Stephen SVP, Research & Development | Aquestive Therapeutics, Inc. (AQST) | 10-Mar-24 | Payment of Exercise | 1,687 | $4.88 | $8,232.56 | (< 1%) 259.65K to 257.96K | |
| 12-Mar-24 1:46 PM View: | Jung Cassie SVP, Operations | Aquestive Therapeutics, Inc. (AQST) | 10-Mar-24 | Payment of Exercise | 1,132 | $4.88 | $5,524.16 | (< 1%) 240.93K to 239.8K | |
| 12-Mar-24 1:47 PM View: | Barber Daniel President and CEO | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-24 | Payment of Exercise | 37,938 | $4.88 | $185,137.00 | (4%) 883.3K to 845.36K | |
| 12-Mar-24 1:47 PM View: | Toth A Ernest Jr SVP, Chief Financial Officer | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-24 | Payment of Exercise | 11,705 | $4.88 | $57,120.40 | (5%) 260.0K to 248.29K | |
| 12-Mar-24 1:47 PM View: | Braender Lori J SVP, General Counsel | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-24 | Payment of Exercise | 10,530 | $4.88 | $51,386.40 | (3%) 323.76K to 313.23K | |
| 12-Mar-24 1:46 PM View: | Jung Cassie SVP, Operations | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-24 | Payment of Exercise | 8,300 | $4.88 | $40,504.00 | (3%) 249.23K to 240.93K | |
| 12-Mar-24 1:46 PM View: | Wargacki Stephen SVP, Research & Development | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-24 | Payment of Exercise | 11,269 | $4.88 | $54,992.70 | (4%) 270.92K to 259.65K | |
| 12-Mar-24 1:45 PM View: | Schobel Alexander Mark Chief Innovation/Tech Officer | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-24 | Payment of Exercise | 5,895 | $4.88 | $28,767.60 | (< 1%) 1.04M to 1.03M | |
| 12-Mar-24 1:47 PM View: | Boyd Peter E. See Remark | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-24 | Payment of Exercise | 8,370 | $4.88 | $40,845.60 | (3%) 246.0K to 237.63K | |
| 12-Mar-24 1:45 PM View: | Schobel Alexander Mark Chief Innovation/Tech Officer | Aquestive Therapeutics, Inc. (AQST) | 08-Mar-24 | Private Sale (Planned) | 25,000 | $5.19 | $129,685.00 | (2%) 1.07M to 1.04M | |
| 11-Mar-24 10:36 AM View: | Braender Lori J SVP, General Counsel | Aquestive Therapeutics, Inc. (AQST) | 07-Mar-24 | Grant | 135,000 | -- | -- | 72% 188.76K to 323.76K | |
| 11-Mar-24 10:34 AM View: | Wargacki Stephen SVP, Research & Development | Aquestive Therapeutics, Inc. (AQST) | 07-Mar-24 | Grant | 112,500 | -- | -- | 71% 158.42K to 270.92K | |
| 11-Mar-24 10:36 AM View: | Schobel Alexander Mark Chief Innovation/Tech Officer | Aquestive Therapeutics, Inc. (AQST) | 07-Mar-24 | Grant | 82,500 | -- | -- | 8% 982.87K to 1.07M | |
| 11-Mar-24 10:35 AM View: | Boyd Peter E. See Remark | Aquestive Therapeutics, Inc. (AQST) | 07-Mar-24 | Grant | 86,250 | -- | -- | 54% 159.75K to 246.0K | |
| 11-Mar-24 10:35 AM View: | Kraus Carl N Chief Medical Officer | Aquestive Therapeutics, Inc. (AQST) | 07-Mar-24 | Grant | 112,500 | -- | -- | 75% 150.0K to 262.5K | |
| 11-Mar-24 10:35 AM View: | Jung Cassie SVP, Operations | Aquestive Therapeutics, Inc. (AQST) | 07-Mar-24 | Grant | 101,250 | -- | -- | 68% 147.98K to 249.23K | |
| 11-Mar-24 10:35 AM View: | Barber Daniel President and CEO | Aquestive Therapeutics, Inc. (AQST) | 07-Mar-24 | Grant | 242,600 | -- | -- | 38% 640.7K to 883.3K | |
| 11-Mar-24 10:36 AM View: | Toth A Ernest Jr SVP, Chief Financial Officer | Aquestive Therapeutics, Inc. (AQST) | 07-Mar-24 | Grant | 120,000 | -- | -- | 86% 140.0K to 260.0K | |
| 09-Aug-23 4:30 PM View: | Kraus Carl N Chief Medical Officer | Aquestive Therapeutics, Inc. (AQST) | 09-Aug-23 | Grant | 150,000 | -- | -- | 100% 0 to 150.0K | |
| 11-Mar-24 10:35 AM View: | Jung Cassie SVP, Operations | Aquestive Therapeutics, Inc. (AQST) | 10-Mar-23 | Payment of Exercise | 1,365 | -- | -- | (< 1%) 149.34K to 147.98K | |
| 11-Mar-24 10:34 AM View: | Wargacki Stephen SVP, Research & Development | Aquestive Therapeutics, Inc. (AQST) | 10-Mar-23 | Payment of Exercise | 1,981 | $0.79 | $1,572.32 | (1%) 160.4K to 158.42K | |
| 09-Mar-23 3:07 PM View: | Boyd Peter E. See Remark | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-23 | Grant | 100,000 | -- | -- | 168% 59.53K to 159.53K | |
| 09-Mar-23 3:07 PM View: | Jung Cassie SVP, Operations | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-23 | Grant | 110,000 | -- | -- | 284% 38.79K to 148.79K | |
| 09-Mar-23 3:07 PM View: | Marshall Ken W. SVP, Chief Commercial Officer | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-23 | Grant | 150,000 | -- | -- | 10381% 1.45K to 151.44K | |
| 09-Mar-23 3:06 PM View: | Barber Daniel President and CEO | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-23 | Grant | 447,000 | -- | -- | 231% 193.7K to 640.7K | |
| 09-Mar-23 3:05 PM View: | Toth A Ernest Jr SVP, Chief Financial Officer | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-23 | Grant | 140,000 | -- | -- | 100% 0 to 140.0K | |
| 09-Mar-23 3:06 PM View: | Braender Lori J SVP, General Counsel | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-23 | Grant | 150,000 | -- | -- | 387% 38.76K to 188.76K | |
| 09-Mar-23 3:06 PM View: | Wargacki Stephen SVP, Research & Development | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-23 | Grant | 135,000 | -- | -- | 501% 26.96K to 161.96K | |
| 09-Mar-23 3:07 PM View: | Schobel Alexander Mark Chief Innovation/Tech Officer | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-23 | Grant | 100,000 | -- | -- | 11% 882.87K to 982.87K | |
| 15-Jun-22 10:24 AM View: | Boyd Peter E. SVP-Bus. Process & Info. Tech. | Aquestive Therapeutics, Inc. (AQST) | 14-Jun-22 | Private Purchase | 5,000 | $0.81 | $4,050.00 | 9% 54.53K to 59.53K | |
| 10-Jun-22 5:26 PM View: | Schobel Alexander Mark Chief Innovation/Tech Officer | Aquestive Therapeutics, Inc. (AQST) | 08-Jun-22 | Private Purchase | 45,871 | $0.96 | $44,036.20 | 5% 837.0K to 882.87K | |
| 10-Jun-22 5:27 PM View: | Barber Daniel Chief Executive Officer | Aquestive Therapeutics, Inc. (AQST) | 08-Jun-22 | Private Purchase | 91,743 | $0.96 | $88,073.30 | 90% 101.96K to 193.7K | |
| 10-Jun-22 5:26 PM View: | Boyd Peter E. SVP-Bus. Process & Info. Tech. | Aquestive Therapeutics, Inc. (AQST) | 08-Jun-22 | Private Purchase | 2,293 | $0.96 | $2,201.28 | 4% 52.24K to 54.53K | |
| 10-Jun-22 5:26 PM View: | Braender Lori J General Counsel | Aquestive Therapeutics, Inc. (AQST) | 08-Jun-22 | Private Purchase | 13,761 | $0.96 | $13,210.60 | 55% 25.0K to 38.76K | |
| 27-Aug-21 1:39 PM View: | Kendall Keith J CEO and President Director | Aquestive Therapeutics, Inc. (AQST) | 26-Aug-21 | Gift | 1,000 | -- | -- | < 1% 637.15K to 638.15K | |
| 27-Aug-21 1:39 PM View: | Kendall Keith J CEO and President Director | Aquestive Therapeutics, Inc. (AQST) | 26-Aug-21 | Gift | 1,000 | -- | -- | (< 1%) 638.15K to 637.15K | |
| 01-Jun-21 4:11 PM View: | Cochran John Director | Aquestive Therapeutics, Inc. (AQST) | 10-May-21 | Gift | 37,500 | -- | -- | (27%) 136.99K to 99.49K | |
| 16-Mar-21 8:20 PM View: | Cochran John Director | Aquestive Therapeutics, Inc. (AQST) | 12-Mar-21 | Acquisition (other) | 61,901 | -- | -- | 82% 75.08K to 136.99K | |
| 16-Mar-21 8:20 PM View: | Bratton Douglas K 10% Owner | Aquestive Therapeutics, Inc. (AQST) | 12-Mar-21 | Acquisition (other) | 1,783,580 | -- | -- | 15% 11.52M to 13.3M | |
| 16-Mar-21 8:20 PM View: | Bratton Douglas K 10% Owner | Aquestive Therapeutics, Inc. (AQST) | 12-Mar-21 | Disposition (other) | 3,475,910 | -- | -- | (26%) 13.3M to 9.82M | |
| 16-Mar-21 8:20 PM View: | Bratton Douglas K 10% Owner | Aquestive Therapeutics, Inc. (AQST) | 09-Mar-21 | Gift | 62,500 | -- | -- | (< 1%) 11.58M to 11.52M | |
| 10-Feb-21 8:17 PM View: | Schobel Alexander Mark Chief Innovation/Tech Officer | Aquestive Therapeutics, Inc. (AQST) | 10-Feb-21 | Market Sale (Planned) | 23,460 | $6.75 | $158,355.00 | (3%) 860.46K to 837.0K | 1% |
| 10-Feb-21 8:17 PM View: | Schobel Alexander Mark Chief Innovation/Tech Officer | Aquestive Therapeutics, Inc. (AQST) | 09-Feb-21 | Market Sale (Planned) | 11,540 | $6.75 | $77,895.00 | (1%) 872.0K to 860.46K | 1% |
| 09-Feb-21 4:00 PM View: | Schobel Alexander Mark Chief Innovation/Tech Officer | Aquestive Therapeutics, Inc. (AQST) | 08-Feb-21 | Market Sale (Planned) | 40,792 | $6.50 | $265,148.00 | (4%) 912.79K to 872.0K | (1%) |
| 04-Jan-21 4:05 PM View: | Kendall Keith J CEO and President Director | Aquestive Therapeutics, Inc. (AQST) | 30-Dec-20 | Gift | 2,000 | -- | -- | < 1% 639.15K to 641.15K | |
| 04-Jan-21 4:05 PM View: | Kendall Keith J CEO and President Director | Aquestive Therapeutics, Inc. (AQST) | 30-Dec-20 | Gift | 2,000 | -- | -- | (< 1%) 641.15K to 639.15K | |
| 19-Aug-20 8:55 AM View: | Maxwell John T. SVP-Chief Financial Officer | Aquestive Therapeutics, Inc. (AQST) | 18-Aug-20 | Market Sale (Planned) | 3,000 | $8.00 | $24,000.00 | (2%) 153.61K to 150.61K | 19% |
| 02-Jul-20 4:00 PM View: | Schobel Alexander Mark Chief Innovation/Tech Officer | Aquestive Therapeutics, Inc. (AQST) | 30-Jun-20 | Option Exercise | 333 | -- | -- | < 1% 912.55K to 912.89K | |
| 02-Jul-20 4:00 PM View: | Kendall Keith J CEO and President Director | Aquestive Therapeutics, Inc. (AQST) | 30-Jun-20 | Option Exercise | 333 | -- | -- | < 1% 638.96K to 639.3K |
